The Role of Angiotensinogen Gene Polymorphism in the Pathogenesis of Non-familial Sick Sinus Syndrome

NCT ID: NCT01310920

Last Updated: 2011-03-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evidence has been documented for the close relationship between the arrhythmia pathogenesis and the gene expression in renin-angiotensin system. However, it remains unclear for involvement of RAS in the pathogenesis of non-familial sick sinus syndrome. The researchers thus investigated the possible relationship between non-familial sick sinus syndrome and the polymorphism and haplotype of the AGT promoter.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sick Sinus Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sick sinus syndrome

observation

Intervention Type OTHER

genotyping

control

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

observation

genotyping

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* sick sinus syndrome

Exclusion Criteria

* 1.Severe systemic disease.
* 2.Acute coronary syndrome.
* 3.bradycardia with reversible cause.
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

China Medical University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

China Medical University hospital

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jan-Yow Chen, M.D.

Role: PRINCIPAL_INVESTIGATOR

China Medical University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

China Medical University Hospital

Dawan, Taiwan, Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jan-Yow Chen, MD

Role: CONTACT

+886-4-22062121 ext. 2311

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jan-Yow Chen, M.D.

Role: primary

+886-4-22062121 ext. 2311

References

Explore related publications, articles, or registry entries linked to this study.

Mangrum JM, DiMarco JP. The evaluation and management of bradycardia. N Engl J Med. 2000 Mar 9;342(10):703-9. doi: 10.1056/NEJM200003093421006. No abstract available.

Reference Type BACKGROUND
PMID: 10706901 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DMR99-IRB-316

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.